ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 24 Issue : 2
Current Issue Archive Popular Article Ahead of Print

 
A promising new inotrope: levosimendan [Anatol J Cardiol]
Anatol J Cardiol. 2010; 10(2): 176-182 | DOI: 10.5152/akd.2010.045  

A promising new inotrope: levosimendan

Hakan Fotbolcu1, Dursun Duman2
1Department of Cardiology, Göztepe Medical Park Hospital, İstanbul, Turkey
2Department of Cardiology Haydarpasa Numune Training and Research Hospital, İstanbul

Intravenous positive inotropic agents are commonly used to treat the patients with acute decompensated heart failure due to left ventricular systolic dysfunction. Although these agents seem to be beneficial for improving symptoms of heart failure in the short-term; it has been reported that they are associated with increased mortality and morbidity. Levosimendan is a new calcium sensitizer and K-ATP channel opener, has emerged as an alternative option of pharmacologic inotropic support in patients with decompensated heart failure. Recent reports on levosimendan's use in severe heart failure demonstrated that this agent is more favorable drug compared with conventional inotropic agents, though its better profile in terms of myocardial efficiency has not been completely understood. This review summarizes the evidence from current scientific literature including our recent trials regarding the mechanism of action, efficiency and the use of levosimendan.

Keywords: Levosimendan, heart failure, positive inotropic agents, clinical trials


Hakan Fotbolcu, Dursun Duman. A promising new inotrope: levosimendan. Anatol J Cardiol. 2010; 10(2): 176-182


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2019 Turkish Society of Cardiology